Visugromab (Powder)
Visugromab (CTL-002) (Powder) is a GDF-15 neutralizing IgG4 mAb. Visugromab (Powder) has synergistic anticancer activity with the anti-PD1 antibody Nivolumab (HY-P9903) and can effectively act on PD-1/PD-L1 relapsed/refractory metastatic solid tumors. Recommend Isotype Controls: Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) [1].
Product Specifications
CAS Number
[2556646-63-8]
Product Name Alternative
CLT-002 (Powder)
UNSPSC
12352203
Target
PD-1/PD-L1; TGF-beta/Smad
Related Pathways
Immunology/Inflammation; Stem Cell/Wnt; TGF-beta/Smad
Field of Research
Cancer
Smiles
[Visugromab(Powder)]
References & Citations
[1]Necchi A, et al. Neutralizing GDF-15 in muscle-invasive bladder cancer (MIBC) : A neoadjuvant immunotherapy trial of visugromab (CTL-002) in combination with the anti-PD1 antibody nivolumab (NEO-GDFATHER) [J]. 2023.|[2]Melero I, et al. Neutralizing GDF-15 can overcome anti-PD-1 and anti-PD-L1 resistance in solid tumours. Nature. 2025 Jan;637 (8048) :1218-1227.
Shipping Conditions
Room temperature
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-P99100A/
Scientific Category
Inhibitory Antibodies
Clinical Information
No Development Reported
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
